Abstract
BackgroundAlthough the prognosis for Lupus Nephritis (LN) has dramatically improved with aggressive immunosuppressive therapies, these drugs carry significant side effects. To improve the effectiveness of these drugs, biomarkers of renal flare cycle could be used to detect the onset, severity, and responsiveness of kidney relapses, and to modify therapy accordingly. However, LN is a complex disease and individual biomarkers have so far not been sufficient to accurately describe disease activity. It has been postulated that biomarkers would be more informative if integrated into a pathogenic-based model of LN.ResultsThis work is a first attempt to integrate human LN biomarkers data into a model of kidney inflammation. Our approach is based on a system of differential equations that capture, in a simplified way, the complexity of interactions underlying disease activity. Using this model, we have been able to fit clinical urine biomarkers data from individual patients and estimate patient-specific parameters to reproduce disease dynamics, and to better understand disease mechanisms. Furthermore, our simulations suggest that the model can be used to evaluate therapeutic strategies for individual patients, or a group of patients that share similar data patterns.ConclusionsWe show that effective combination of clinical data and physiologically based mathematical modeling may provide a basis for more comprehensive modeling and improved clinical care for LN patients.
Highlights
The prognosis for Lupus Nephritis (LN) has dramatically improved with aggressive immunosuppressive therapies, these drugs carry significant side effects
We show that effective combination of clinical data and mathematical modeling can improve our understanding of disease dynamics, and can be used to gain insight into why failures occur with the way LN is currently treated
Comparison of simulated urine MCP-1 (uMCP-1) and uP:C dynamics during flare cycle with patients data As disease progression and response to treatment varies from one patient to another, we choose to separately calibrate the mathematical model to each individual patient clinical data shown in Fig. 1 and Fig. 2
Summary
The prognosis for Lupus Nephritis (LN) has dramatically improved with aggressive immunosuppressive therapies, these drugs carry significant side effects. To improve the effectiveness of these drugs, biomarkers of renal flare cycle could be used to detect the onset, severity, and responsiveness of kidney relapses, and to modify therapy . Anti-DNA antibodies or immune complexes which contain these antibodies, are deposited in the kidney, which results in activation of the complement system, This leads to tissue inflammation and damage, and the consequent release of DNA, nuclear material, and cell debris. These products of tissue damage can serve as antigens, further stimulating the immune system and increasing the intrarenal inflammatory response. LN is typically characterized by exacerbations/relapses of disease activity (flares) and remissions (after treatment)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
